Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Exogenous mitochondria added on benefits for cellular prion protein overexpression in adipose-derived mesenchymal stem cells treatment on intracranial hemorrhage rat.

Lin KC., Yeh JN., Sung PH., Yin TC., Chiang JY., Huang CR.

Animal Study on Systemic / IV, published in J Mol Histol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Mol Histol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40080193
PMCID
PMC11906555
DOI
10.1007/s10735-025-10382-x

Abstract (original English)

We examined whether combined exogenous mitochondria (Ex Mito ) and cellular prion protein overexpression (Ove-PrP C ) in adipose-derived mesenchymal stem cell (Ove-PrP C in ADMSCs) therapy is superior to a single therapy for protecting the brain against intracranial hemorrhage (ICH) in rats. In vitro, compared with the control group, Ex Mito transfusion into recipient cells (i.e., N2a cells) significantly increased under hypoxic conditions (P < 0.001) and augmented ρ0 cell proliferation and cell-cycle activation (P < 0.001). PrP C-OE in ADMSCs exhibited higher resistance to H 2 O 2 -induced cell senescence and mitochondrial and DNA damage compared to ADMSCs (P < 0.001). Rats were categorized into group 1 (sham-control), 2 (ICH), 3 [ICH + Ex Mito (350 μg) by intracranial injection at 3 h after ICH], 4 [ICH + PrP C-OE in ADMSCs (6.0 × 10 5 cells) and intracranial injection and 1.2 × 10 6 cells by intravenous injection)], and 5 (ICH + combined Ex Mito + PrP C-OE in ADMSCs). By day 28, the brain infarct volume, brain infarct area, inflammatory cell infiltration, and biomarkers for DNA and mitochondrial damage were highest in group 2, lowest in group 1, and significantly lower in group 5 than in groups 3 and 4. NeuN cells exhibited the opposite pattern for brain infarct volume, and neurological function (corner test) significantly improved in groups 3 and 4, with further improvement

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMesenchymal Stem CellsMitochondriaRatsMesenchymal Stem Cell TransplantationPrion ProteinsIntracranial HemorrhagesMaleAdipose TissueDisease Models, Animal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research